

Companion Diagnostic Tests.

Testing solutions for precision medicine in Cancer,

Cancer Type	CDx Test name	Description	TAT	Sample Type	Price (NGN)	Partner Price (NGN)	Notes
LUNG CANCER	Lung Cancer Panel (Multi gene panel)	<p>Detection of actionable mutations for Lung Cancer covering up to 167 variants (85 DNA mutations and 82 RNA Fusions) in 11 genes</p> <p>-EGFR, HER2, KRAS and BRAF genes.</p> <p>-Gene fusions in ALK, ROS1, RET, Met exon 14 Skipping, NTRK1, NTRK2 and NTRK3 genes.</p> <p>The Lung Cancer Panel identifies all NCCN (National Comprehensive Cancer Network) recommended biomarkers.</p>	7-10 working days	Formalin-fixed paraffin-embedded (FFPE) tumor tissue (with min of 30% Tumour content)	3,059,047.78	TBC	requests at least 4 samples
	EGFR Mutations	Detects up to 29 mutations in the EGFR gene including Exon 19 deletions , Insertions, Mutations on S768I, L861Q and/or G719X mutations, T790M, L858R	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	905,304.54	TBC	requires a min of 5 samples
	RET Gene fusions	detection of up to 9 RET gene fusions in human RNA	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	Call	TBC	requires a min of 5 samples
	MET exon 14 Skipping mutations	detection of <i>MET</i> exon14 skipping mutation in human RNA	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	Call	TBC	requires a min of 5 samples
	EML4/ALK Fusion (2 gene panel)	detection of up to 21 <i>EML4-ALK</i> fusions in human RNA extracted from NSCLC patients	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	Call	TBC	requires a min of 5 samples
	ALK and ROS1 Gene Fusions (2 gene panel)	Detects up to 14 <i>ALK</i> gene fusions and 14 <i>ROS1</i> gene fusions in human RNA	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	Call	TBC	requires a min of 5 samples

Companion Diagnostic Tests.

Testing solutions for precision medicine in Cancer,

	EGFR/ROS1/ALK (3 gene panel)	Detection of up to 58 variants in <i>EGFR</i> , <i>ALK</i> , and <i>ROS1</i> genes in human DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples	TBC	FFPE tumor tissue (with min of 30% Tumour content)	Call	TBC	requires a min of 5 samples
Cancer Type	Test name	Description	TAT	Sample Type	Price (NGN)	B2BPrice (NGN)	Notes
Colorectal Cancer	KRAS	Detection of the main mutations of exon 2 (codons 12, 13), of exon 3 (codons 59, 61) and of exon 4 (codons 117, 146) of the gene KRAS	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	738,739.54	TBC	requires a min of 5 samples
	NRAS	Detection of the main mutations of exon 2 (codons 12, 13), of exon 3 (codons 59, 61) and of exon 4 (codons 117, 146) of NRAS gene	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	697,552.54	TBC	requires a min of 5 samples
	KRAS/NRAS	Detection of Mutations in both KRAS and NRAS gene	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	1,180,526.67	TBC	requires a min of 5 samples
	KRAS/NRAS/BRAF	detection of up to 31 somatic mutations of the <i>KRAS</i> , <i>NRAS</i> , and <i>BRAF</i> genes in human DNA extracted from formalin-fixed paraffin-ded (FFPE) tissue	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	1,528,550.65	TBC	requires a min of 5 samples
	MSI	Tracks variations in microsatellite lengths across eight novel biomarkers (<i>EIF4E3</i> , <i>IFT140</i> , <i>PPP1CC</i> , <i>UBAC2</i> , <i>PRR5-ARHGAP8</i> , <i>ACVR2A</i> , <i>TAOK3</i> , <i>RBM14-RBM4</i>) presence of MSI indicates a potential defect in the mismatch repair (dMMR) mechanisms.	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	710,400.66	TBC	requires a min of 5 samples
Colon, lung, thyroid, melanoma, also brain, ovarian, non-Hodgkin Lyphoma	BRAF	Detection of V600E, V600K, V600E2, V600R, V600D2,V600A	5 to 7 working days	FFPE tumor tissue (with min of 30% Tumour content)	589,800.54	TBC	requires a min of 5 samples

Companion Diagnostic Tests.

Testing solutions for precision medicine in Cancer,

Multi Gene Panel		Detection of up to 118 variants across 9 genes (<i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> , <i>ROS1</i> , <i>RET</i> , <i>HER2</i> , <i>ALK</i> and <i>EGFR</i>). It is designed to assist in identifying clinically relevant biomarkers for patients with non-small cell lung cancer (NSCLC) who may be eligible for approved targeted therapies.	Available from March 2025	FFPE tumor tissue (with min of 30% Tumour content)	3,075,499.13	TBC	requires a min of 6 samples
Breast Cancer	PIK3CA	Detection of 11 mutations which are the main mutations of codons 345, 420, 542, 545, 546, 1047, 1049 of the PIK3CA gene	Available from March 2025	FFPE tumor tissue (with min of 30% Tumour content)	809,490.00	TBC	
	HER 2	Detection of up to 13 variants in human DNA extracted from formalin-fixed paraffin-ded (FFPE) tissue	Available from March 2025	FFPE tumor tissue (with min of 30% Tumour content)	706,304.54	TBC	requires a min of 5 samples
	ESR1- Liquid	Detection of mutations in Estrogen receptor gene and to identify patients who develop resistance to Endocrine Therapy and are eligible for 2 nd line therapy.	Available from March 2025	Liquid Biopsy	1,386,500.00	Call	
Breast/Prostrate/Ovarian	BRCA 1& 2	Detection of mutations in BRCA 1 and 2 genes that are pathogenic and have clinical significance.	Available	FFPE tumor tissue (with min of 30% Tumour content) Whole Blood	Starting price is 1,400,000.00	TBC	TBC
	HRD Focus	Detection in the Homologous recombinant repair (HRR) pathway and any Homologous recombinant deficiency (HRD) Genes in focus BRCA 1& 2	Available from 2nd Qtr 2025	FFPE tumor tissue (with min of 30% Tumour content)	TBC	TBC	TBC

Companion Diagnostic Tests.

Testing solutions for precision medicine in Cancer,

	HRD Complete	Detects mutations in 20 Homologous recombinant repair (HRR) genes and any Homologous recombinant deficiency (HRD) ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CHEK1, CHEK2, FANCA, FANCL, HDAC2, PALB2, PPP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, TP53.	Available from 2nd Qtr 2025	FFPE tumor tissue (with min of 30% Tumour content)	TBC	TBC	TBC
Cancer Immunology	PD-L1		15 Working days	FFPE tumor tissue (with min of 30% Tumour content)	690,000	TBC	TBC
	PD-1		TBC	TBC	TBC	TBC	TBC
Contact us for other mutations of interest.							
Kindly Note that prices are subject to change without notice							

Test Request

Send an email to Customercare@biologix.com.ng or biologixlabsng@gmail.com or call 08053072221

We will send you instructions on how to proceed with your selected test.

Thank you for Choosing Biologix

Companion Diagnostic Tests.

Testing solutions for precision medicine in Cancer,

GUIDE FOR APPROVED TARGETED THERAPIES

TUMOR TYPES	BIOMARKERS	FDA-APPROVED THERAPY
Solid Tumors	<i>NTRK1/2/3</i> fusions	Vitrakvi® (larotrectinib) or Rozlytrek® (entrectinib)
	MSI-H	Keytruda® (pembrolizumab)
	<i>RET</i>	Retevmo (selpercatinib)
Non-Small Cell Lung Cancer (NSCLC)	<i>EGFR</i> exon 20 T790M alterations	Tagrisso® (osimertinib)
	<i>EGFR</i> exon 19 deletions and <i>EGFR</i> exon 21 L858R alterations	<i>EGFR</i> Tyrosine Kinase Inhibitors (TKI) approved by FDA ¹
	<i>EGFR</i> exon 20 insertion mutations	EXKIVITY® (mobocertinib)
	<i>ROS1</i> fusions	Rozlytrek® (entrectinib)
	MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping	Tabrecta® (capmatinib)
	<i>ALK</i> rearrangements	Alecensa® (alectinib), Alunbrig® (brigatinib), Xalkori® (crizotinib), or Zykadia® (ceritinib)
	<i>BRAF</i> V600E	Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) or BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
Melanoma	<i>BRAF</i> V600E	<i>BRAF</i> Inhibitors approved by FDA*
	<i>BRAF</i> V600E and V600K	Mekinist® (trametinib) or <i>BRAF</i> /MEK Inhibitor Combinations approved by FDA ¹
	<i>BRAF</i> V600 mutation-positive	Tecentriq® (atezolizumab) in combination with Cotellic® (cobimetinib) and Zelboraf® (vemurafenib)
Breast Cancer	<i>ERBB2</i> (HER2) amplification	Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)
	<i>PIK3CA</i> C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations	Piqray® (alpelisib)
Colorectal Cancer	<i>KRAS</i> wild-type (absence of mutations in codons 12 and 13)	Erbitux® (cetuximab)
	<i>KRAS</i> wild-type (absence of mutations in exons 2, 3 and 4) and <i>NRAS</i> wild-type (absence of mutations in exons 2, 3 and 4)	Vectibix® (panitumumab)
	<i>BRAF</i> V600E	BRAFTOVI® (encorafenib) in combination with cetuximab
Ovarian Cancer	<i>BRCA1/2</i> alterations	Lynparza® (olaparib)
Cholangiocarcinoma	<i>FGFR2</i> fusions and select rearrangements	Pemazyre™ (pemigatinib) or Truseltiq™ (infigratinib)
Prostate Cancer	Homologous Recombination Repair (<i>HRR</i>) gene (<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>BARD1</i> , <i>BRIP1</i> , <i>CDK12</i> , <i>CHEK1</i> , <i>CHEK2</i> , <i>FANCL</i> , <i>PALB2</i> , <i>RAD51B</i> , <i>RAD51C</i> , <i>RAD51D</i> and <i>RAD54L</i>) alterations	Lynparza® (olaparib)
	<i>BRCA1/2</i> alterations	Rubraca® (rucaparib) or AKEEGATM (niraparib and abiraterone acetate dual action tablet)